Cell loss no greater with femtosecond lasers

Article

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines.

Penetrating keratoplasty (PK) with a femtosecond laser offers good surgical results and endothelial cell loss numbers similar to those found for PK using standard trephines, according to Mike Holzer and co-workers at the International Vision Correction Research Centre, Heidelberg University, Germany.

Eleven eyes of 10 subjects underwent uneventful PK with a femtosecond laser. Endothelial cell counts were taken on the corneal donor buttons prior to surgery and measurements were taken at 12 and 24 months postoperatively using a specular microscope.

Preoperative cell counts ranged between 2,300 and 2,750 cells/mm2. At 24 months postoperatively, all corneal transplants were clear and visual acuity had improved from preoperative levels. The postoperative cell counts ranged between 1,350 and 2,100 cells/mm2, whilst the median cell loss was recorded as 35.9%.

It was concluded that cell loss is similar in patients undergoing PK with a femtosecond laser and in those undergoing treatment using conventional trephines.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.